Medication Type for T2DM May Affect Severe COVID-19 Outcomes
Premorbid GLP1-RA use, SGLT2i use associated with lower 60-day mortality compared to premorbid DPP4i use
Risk Factors ID’d for COVID-19-Related Death in Diabetes
Risk for COVID-19-related death up in association with male sex, older age, preexisting comorbidities, insulin use
Diabetes Mortality Rates Higher Among Blacks Than Whites
Rate ratios significantly higher in 11 cities; Black-White rate ratio about three times higher in Washington, D.C., than national rate ratio
Mortality Higher for Diabetic Ketoacidosis With COVID-19
Obesity, higher insulin requirements may be associated with higher mortality
Predictors of Death, Discharge ID’d for Diabetes Patients With COVID-19
Younger age, routine metformin therapy, and longer symptom duration on admission positively linked to discharge
Metformin Use for T2DM May Reduce COVID-19 Mortality
Odds of contracting COVID-19, COVID-19-related mortality higher for individuals with diabetes
Hyperglycemia, Hypoglycemia Linked to Poor Outcomes in COVID-19
Admission blood glucose is strong predictor of death among patients admitted directly to the ICU
Risk of Severe COVID-19 Up Among Those With Diabetes
Risk for severe COVID-19 similar among those with type 1 and type 2 diabetes
Admission Hyperglycemia Predicts Mortality in COVID-19
Patients with hyperglycemia had higher cumulative probability of mortality, independent of preexisting diabetes
- Page 1 of 2
- 1
- 2